Skip to main content

Table 5 Antiangiogenic targets

From: Vascular involvement in rheumatic diseases: 'vascular rheumatology'

Endogenous inhibitors

Angiostatin

 

Endostatin

 

Thrombospondin-2

 

Interleukin-4, interleukin-13

 

Platelet factor-4/CXCL4 chemokine

Exogenous inhibitors

Classical disease-modifying antirheumatic drugs

 

Anti-tumor necrosis factor biologics

 

Thalidomide

 

Fumagillin analogs

 

Vascular endothelial growth factor inhibitors

 

Hypoxia-inducible factor heterodimer inhibitors

 

Angiopoietin-1/Tie2 inhibitors

 

αVβ3 integrin inhibitors

 

Microtubule destabilizers (for example, paclitaxel)

 

Others (for example, glitazones)